Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Moderna Inc

3 Vaccine Stocks to Buy Following the Surge in COVID-19 Cases in China

China is battling with its worst COVID-19 outbreak since 2020. Surging cases of a new omicron variant worldwide are raising concerns that another COVID-19 wave is coming, which could drive demand for future vaccine orders. This bodes well for popular vaccine stocks Pfizer (PFE), Moderna (MRNA), and BioNTech (BNTX), and…

StockNews.com

Analyzing Moderna Inc's Short Interest

Moderna Inc's (NASDAQ:MRNA) short percent of float has risen 7.66% since its last report. The company recently reported that it has 17.61 million shares sold short, which is 5.06% of all regular shares that are available for trading.

Benzinga

Moderna's COVID-19 Vaccine Shows Neutralizing Antibody Response In Kids Under 6

Moderna Inc (NASDAQ:MRNA) has announced interim data from the Phase 2/3 KidCOVE study of its COVID-19 vaccine (mRNA-1273) in children six months to under six years. The interim analysis showed that two 25 μg doses of mRNA-1273 in participants 6 months to under six years met the primary endpoint with robust neutralizing antibody…

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Why Moderna Shares Are Trading Higher Today

Moderna Inc (NASDAQ: MRNA) shares are trading higher Tuesday after the company announced two new vaccine candidate developments.

Benzinga

Moderna Bolsters Its Pipeline With Two New mRNA-Based Vaccine Programs

Moderna Inc (NASDAQ:MRNA) expands its mRNA pipeline with two new development programs ahead of Annual Vaccines Day, building on Moderna's experience with Spikevax, its COVID-19 vaccine. The development programs include a combination respiratory vaccine candidate and a new program against all four endemic human coronaviruses (HCoV). First, Moderna is launching a respiratory combination…

Benzinga

5 Cheap Value Stocks to Add to Your Portfolio

Despite the latest federal interest rate hikes, undervalued stocks with impressive financials are expected to deliver solid returns in the coming months. So, we think it could be wise to scoop up quality stocks Moderna (MRNA), Bayer (BAYRY), Henkel (HENKY), AGCO (AGCO), and Penske Automotive (PAG), which are currently trading…

StockNews.com

The Future of Boosters Is Somewhere Between Unnecessary and Urgent

Until there’s a universal coronavirus vaccine, the future of additional shots is a murky work in progress—but more rounds seem increasingly likely.

Businessweek

Read news from The Economist, FT, and more,
with one subscription

Like Pfizer, Moderna Seeks FDA Approval For Fourth COVID-19 Shot Or Second Booster Dose

Moderna Inc (NASDAQ: MRNA) has asked the FDA to authorize a

Benzinga

Health Canada Approves Moderna's COVID-19 Vaccine For Kids Aged 6-11 Years

Health Canada has approved Moderna Inc's (NASDAQ:MRNA) mRNA COVID-19 vaccine, Spikevax, two-dose series of 50 µg per dose to prevent COVID-19 in children aged six to11 years. The announcement follows the recent authorization of the Company's COVID-19 vaccine in the same age group in both Australia and the European Union. "Health Canada was…

Benzinga

Alnylam Hits Pfizer, Moderna With Patent Infringement Suits

Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) has filed separate lawsuits in the Delaware federal court against Pfizer Inc (NYSE:PFE) and Moderna Inc (NASDAQ:MRNA), seeking damages for infringement of a patent in the manufacture and sale of their mRNA COVID-19 vaccines. Alnylam said it was seeking compensation for the use of its lipid nanoparticles (LNP) technology that carries and delivers…

Benzinga

Here's Why Moderna Shares Are Rising

Moderna Inc (NASDAQ: MRNA) shares are trading higher by 7.0% at $158.42. The company announced today it has reached an agreement with Japan to supply an additional 70 million doses of its COVID-19 booster vaccine.

Benzinga

Moderna Moves Forward With Second HIV Vaccine Trial

Moderna Inc (NASDAQ:MRNA) has dosed the first participant in a clinical trial of an experimental human immunodeficiency virus (HIV) trimer mRNA vaccine (mRNA-1574). The open-label, multicenter, randomized Phase 1 trial (HVTN 302) is designed to evaluate the safety and immunogenicity of experimental HIV trimer mRNA vaccines. The primary hypothesis is that the soluble…

Benzinga

GeoVax Labs Retains CATO SMS To Manage Its Mid-Stage COVID-19 Vaccine Trials

GeoVax Labs Inc (NASDAQ:GOVX) has engaged CATO SMS to manage its two ongoing Phase 2 trials of its COVID-19 vaccine candidate, GEO-CM04S1. One is testing the safety and effectiveness of GEO-CM04S1 compared to the Pfizer Inc (NASDAQ:PFE) / BioNTech SE (NASDAQ:BNTX) in immunosuppressed patients with blood cancer. The other trial is testing GEO-CM04S1 as a booster in…

Benzinga

Here's Why Moderna Shares Are Rising On Monday

Moderna Inc (NASDAQ: MRNA) shares are trading higher by 18.9% at $164.27 after the company announced the first participant has been dosed in a clinical trial of an experimental HIV trimer mRNA vaccine.

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Moderna Starts Dosing In Mid-Stage Omicron-Specific Bivalent Booster Candidate

Moderna Inc (NASDAQ: MRNA) has

Benzinga

Moderna Plans Vaccines Against 15 Pathogens With Future Pandemic Potential

Moderna Inc (NASDAQ: MRNA) plans to develop and begin testing vaccines targeting 15 pathogens identified as the biggest public health risk by WHO and CEPI by 2025. The Company also said it would permanently wave its COVID-19 vaccine patents for shots intended for certain low- and middle-income countries. At its global public health strategy,…

Benzinga

Moderna To Set Up mRNA Vaccine Manufacturing Facility In Kenya

Moderna Inc (NASDAQ:MRNA) would set up a manufacturing facility in Kenya, its first in Africa, to produce messenger RNA (mRNA) vaccines, including COVID-19 shots. Moderna expects to invest about $500 million in the Kenyan facility and supply as many as 500 million doses of mRNA vaccines to the continent each year. It also…

Benzinga

Arbutus Hits Moderna With New Suit Claiming COVID-19 Vaccine Patent(s)

Arbutus Biopharma Corporation (NASDAQ: ABUS) and Genevant have sued Moderna Inc (NASDAQ: MRNA) for

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

(MRNA) - Analyzing Moderna Inc's Short Interest

Moderna Inc's (NASDAQ:MRNA) short percent of float has fallen 5.45% since its last report. The company recently reported that it has 15.80 million shares sold short, which is 4.51% of all regular shares that are available for trading.

Benzinga

Will Moderna Be 'One Of The Most Valuable Healthcare Companies' In The World? Steve Weiss Believes So

Moderna Inc (NASDAQ: MRNA) is on the move Thursday following strong quarterly financial results. Short Hills Capital's Steve Weiss decided to pick up additional shares of the commercial-stage biotech company after the report.

Benzinga

What's Going On With Moderna Shares Today?

Moderna Inc (NASDAQ: MRNA) shares are trading higher by 9.7% at $149.11 after the company reported better-than-expected fourth-quarter EPS and sales results and announced a new $3 billion buyback.

Benzinga

Moderna Beats On Q4 Earnings, Announces $3B Buyback; Expects ~$19B In FY22 COVID-19 Vax Sales

Moderna Inc (NASDAQ:MRNA) reports a Q4 EPS of $11.29, a turnaround from an EPS loss of $(0.69) a year ago, beating the consensus estimate of $9.90. The Company clocked Q4 revenues of $7.21 billion compared to just $571 million a year ago, beating the consensus of $6.79 billion. Product sales were $6.9…

Benzinga

Moderna, Thermo Fisher Join Forces To Manufacture COVID-19 Vaccine, Other Drugs

Moderna Inc (NASDAQ: MRNA) has en

Benzinga

Looking Into Moderna Inc's Recent Short Interest

Benzinga

Moderna Adds Three New mRNA-Based Development Programs To Its Pipeline

Moderna Inc (NASDAQ: MRNA) said it is deve

1 2 3 4 5

People

Stéphane Bancel

21 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Centers for Disease Control and Prevention

US Food and Drug Administration

63 stories

National Institutes of Health

62 stories

BNTX

61 stories

Read news from The Economist, FT, and more,
with one subscription

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.